1 May 2024 - As of today, we will adopt Canada’s Drug Agency (CDA-AMC) as our new operating name. ...
1 April 2024 - CADTH has developed a comprehensive and accessible tool to support the validation of economic models used in ...
2 April 2024 - Positive HTA recommendation for reimbursement signifies an important milestone towards public funding to treat eligible patients with ...
29 February 2024 - Last year, CADTH communicated several improvements to our drug reimbursement review program, including a Lean review ...
18 December 2023 - Helping make Canada's drug system more sustainable and better prepared for the future. ...
2 November 2023 - Recommendation based on demonstrated clinical benefit in Phase 3 trial. ...
12 September 2023 - Paladin Labs announced today that CADTH has recommended that Xcopri (cenobamate) be publicly reimbursed as adjunctive therapy ...
18 August 2023 - CADTH is establishing an industry task force that will build upon the recently released guidance for reporting ...
20 July 2023 - As CADTH continues along the path of strategic transformation, we’re working hard to align the evidence products ...
5 June 2023 - Today, CADTH is communicating a series of improvements that will further our ambition to innovate in ...
31 May 2023 - CADTH has partnered with Health Canada, the Institut national d’excellence en santé et en services sociaux (INESSS), ...
16 May 2023 - CADTH, Health Canada, and the Institut national d’excellence en santé et en services sociaux (INESSS) are ...
24 April 2023 - The position statement is a step toward greater transparency of unpublished data and a tangible outcome ...
25 April 2023 - During a 1-year learning period, CADTH expanded its Scientific Advice program to include advice on real-world evidence ...
8 March 2023 - BioCryst Pharmaceuticals today announced that the CADTH Canadian Drug Expert Committee has issued a positive recommendation ...